



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Anti-S protein (RBD) [5F8] Standard Size Ab03059-10.159

This chimeric human antibody was made using the variable domain sequences of the original VHH format for improved compatibility with existing reagents assays and techniques.

**Isotype and Format:** Human IgG1-Fc fusion

**Clone Number:** 5F8

**Alternative Name(s) of Target:** Spike glycoprotein; Receptor Binding Domain; SARS CoV 2 S glycoprotein; COVID-19 Spike protein; RBD; Receptor Binding Domain; S glycoprotein; SARS coronavirus 2 S protein; SARS coronavirus 2 Spike Protein; SARS CoV 2 Spike protein; SARS CoV 2; SARS-CoV-2 S protein; SARSCoV2; SARS-COV-2 S protein; SARS-COV-2 Spike glycoprotein; SARSCOV2 Spike protein; Severe acute respiratory syndrome 2 spike glycoprotein; Severe acute respiratory syndrome virus 2 spike glycoprotein; S glycoprotein; E2; Peplomer protein

**UniProt Accession Number of Target Protein:** P0DTC2

**Published Application(s):** in vitro neutralization, SPR

**Published Species Reactivity:** SARS-CoV-2

**Immunogen:** The original antibody was generated by using phage display technology by biopanning a full synthetic, humanized phage display library with recombinant RBD protein.

**Specificity:** The antibody binds the receptor binding domain (RBD) of the SARS-CoV-2 Spike protein.

**Application Notes:** The binding affinity of the VHH fragment towards SARS-CoV-2 or SARS-CoV RBD was measured using surface plasmon resonance ( $K_d = 0.996$  and  $239,2$  nM respectively). The neutralization activity of the VHH fragment with SARS-CoV-2 pseudotypes or SARS-CoV-2 was tested, the showing half maximal neutralization concentration ( $EC_{50}$ ) of  $0.0009$  µg/mL and  $0.51$  µg/mL respectively. Competition-binding assay showed the clone could just partially prevent binding of SARS-CoV-2 RBD to ACE2. Neutralization assay of the bivalent form of the clone fused with human IgG1 Fc against SARS-CoV-2pp was performed, showing  $EC_{50} = 0.004$  µg/mL (Chi et al, 2020; PMID: 32913273).

**Antibody First Published in:** Chi et al. Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain Nat Commun. 2020 Sep 10;11(1):4528. [PMID:32913273](#)

**Note on publication:** The paper describes the generation and characterization of the antibody.

### Product Form

**Size:** 100 µg Purified antibody.

**Purification:**

Protein A affinity purified

**Supplied In:** PBS with 0.02% Proclin 300.

**Storage Recommendation:** Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

**Concentration:** 1 mg/ml.

Important note - This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.